Last reviewed · How we verify
SUVN-502
At a glance
| Generic name | SUVN-502 |
|---|---|
| Also known as | Masupirdine |
| Sponsor | Suven Life Sciences Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type (PHASE3)
- SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study (PHASE2)
- Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SUVN-502 CI brief — competitive landscape report
- SUVN-502 updates RSS · CI watch RSS
- Suven Life Sciences Limited portfolio CI